Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 373-376

  Girgis, Ragy R ^a   Xu, Xiaoyan ^a   Gil, Roberto B ^a   Hackett, Elizabeth ^a   Ojeil, Najate ^a   Lieberman, Jeffrey A ^a   Slifstein, Mark ^a   Abi Dargham, Anissa ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Dopamine 3; Occupancy; PET; PHNO; Risperidone; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PHNO C 11; RADIOLIGAND; RISPERIDONE; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; NAXAGOLIDE; OXAZINE DERIVATIVE; PROTEIN BINDING;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; DRUG EFFECTS; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE;

ADULT; BRAIN; BRAIN MAPPING; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 84942371408     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.06.027     Document Type: Article

References (21)

1. Abi-Dargham A., Martinez D., Mawlawi O., Simpson N., Hwang D.R., Slifstein M., Anjilvel S., Pidcock J., Guo N.N., Lombardo I., Mann J.J., Van Heertum R., Foged C., Halldin C., Laruelle M. Measurement of striatal and extrastriatal dopamine D-1 receptor binding potential with [C-11]NNC 112 in humans: validation and reproducibility. J. Cerebr. Blood F Met. 2000, 20(2):225-243.
2. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/P, Version 2.0) 1995, Biometrics Research Dept., New York State Psychiatric Institute, New York.
3. 11C]-(+)-PHNO binding in the human brain. J. Cereb. Blood Flow Metab. 2007, 27(4):857-871.
4. Girgis R.R., Xu X., Miyake N., Easwaramoorthy B., Gunn R.N., Rabiner E.A., Abi-Dargham A., Slifstein M. In vivo binding of antipsychotics to D(3) and D(2) receptors: a PET study in baboons with [(11)C]-(+)-PHNO. Neuropsychopharmacology 2011, 36(4):887-895.
5. 11C]-(+)-PHNO. Arch. Gen. Psychiatry 2009, 66(6):606-615.
6. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, Department of Heath, Education and Welfare Publication, Washington DC.
7. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
8. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage 1996, 4(3 Pt 1):153-158.
9. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49(3):231-252.
10. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., Cooper T., Kegeles L., Zarahn E., Abi-Dargham A., Haber S.N., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J. Cereb. Blood Flow Metab. 2003, 23(3):285-300.
11. 11C]-(+)-PHNO. Schizophr. Res. 2011, 131(1-3):63-68.
12. Narendran R., Slifstein M., Guillin O., Hwang Y.Y., Hwang D.R., Scher E., Reeder S., Rabiner E., Laruelle M. The dopamine (D-2/3) receptor agonist positron emission tomography radiotracer [C-11]-(+)-PHNO is a D-3 receptor preferring agonist in vivo. Synapse 2006, 60(7):485-495.
13. Nurnberger J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry 1994, 51(11):849-859. (discussion 863-844).
14. Rabiner E., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., Diwan M., Wilson A.A., McCormick P., Gentile G., Gunn R.N., Laruelle M. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
15. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124(1-2):57-73.
16. 11C]PHNO, and a selective D3 receptor antagonist. Biol. Psychiatry 2010, 68(4):392-399.
17. Searle G., Beaver J.D., Comley R.A., Bani M., Tziortzi A., Slifstein M., Mugnaini M., Griffante C., Wilson A.A., Merlo-Pich E., Houle S., Gunn R., Rabiner E.A., Laruelle M. Imaging dopamine D-3 receptors in the human brain with positron emission tomography, [C-11]PHNO, and a selective D-3 receptor antagonist. Biol. Psychiatry 2010, 68(4):392-399.
18. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5(1):25-43.
19. 11C]-(+)-PHNO. Biol. Psychiatry 2006, 59(5):389-394.
20. Wilson A.A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo Imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48(12):4153-4160.
21. Wilson A.A., McCormick P., Kapur S., Willeit M., Garcia A., Hussey D., Houle S., Seeman P., Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48(12):4153-4160.